WOBURN, Mass. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on Wednesday, November 1, 2023 . This live, interactive, online event will give shareholders and the investment community the opportunity to

WOBURN, Mass. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes through

WOBURN, Mass. , Oct. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q3 2023 business and financial highlights before the opening of the market on October 26, 2023 . The Company will host a conference call at 8:00 a.m., Eastern Time on

WOBURN, Mass. , Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA). As a Proud Sponsor NeuroMetrix will support the NFA’s mission to provide education, support, and advocacy for

WOBURN, Mass. , Sept. 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on October 4, 2023 . This live, interactive, online event will give shareholders and the investment community the opportunity to interact in

WOBURN, Mass. , Aug. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on September 6, 2023 . This live, interactive, online event will give shareholders and the investment community the opportunity to interact in

WOBURN, Mass. , July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes through

WOBURN, Mass. , July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market on July 27, 2023 . The Company will host a conference call at 8:00 a.m., Eastern Time on July 27,

WOBURN, Mass. , July 11, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expansion of its sales force to drive further adoption of Quell ® Fibromyalgia, which is the first and only medical device authorized by the U.S. Food and Drug Administration (FDA) to help reduce the

WOBURN, Mass. , June 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of two large studies that support the clinical utility of DPNCheck screening in people with diabetes. Ke and colleagues developed and validated an algorithm to predict progression from